Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8 to $7.5.
Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8 to $7.5.